Drug Profile
C 9136
Alternative Names: C-9136Latest Information Update: 03 Jul 2006
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Endocrine disorders
Most Recent Events
- 03 Jul 2006 No development reported - Phase-II for Alzheimer's disease in USA (unspecified route)
- 03 Jul 2006 No development reported - Phase-II for Endocrine disorders in USA (unspecified route)
- 31 Aug 2005 Phase-II clinical trials in Endocrine disorders in USA (unspecified route)